Figure S8 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for <i>MTAP</i>-Deleted <i>KRAS</i>-Mutant Pancreatic Cancer

অনুরূপ উপাদানগুলি

• Figure S1 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for <i>MTAP</i>-Deleted <i>KRAS</i>-Mutant Pancreatic Cancer
  অনুযায়ী: Kristina Drizyte-Miller (14961288)
  প্রকাশিত: (2025)
• Figure S2 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for <i>MTAP</i>-Deleted <i>KRAS</i>-Mutant Pancreatic Cancer
  অনুযায়ী: Kristina Drizyte-Miller (14961288)
  প্রকাশিত: (2025)
• Figure S3 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for <i>MTAP</i>-Deleted <i>KRAS</i>-Mutant Pancreatic Cancer
  অনুযায়ী: Kristina Drizyte-Miller (14961288)
  প্রকাশিত: (2025)
• Figure S4 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for <i>MTAP</i>-Deleted <i>KRAS</i>-Mutant Pancreatic Cancer
  অনুযায়ী: Kristina Drizyte-Miller (14961288)
  প্রকাশিত: (2025)
• Figure S5 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for <i>MTAP</i>-Deleted <i>KRAS</i>-Mutant Pancreatic Cancer
  অনুযায়ী: Kristina Drizyte-Miller (14961288)
  প্রকাশিত: (2025)